Inhibikase completes annual meeting filings, board elections finalized

Inhibikase Therapeutics filed a new 8-K confirming the outcome of its 2026 Annual Meeting of Stockholders, held on June 26, 2026 in a virtual-only format via live webcast.¹ The filing also confirms that on June 26, 2026, the company filed the amendment with the Secretary of State of Delaware, and it took effect immediately upon filing.¹

At the meeting, stockholders elected two Class III directors to the board. Arvind Kush and Dennis Berman were elected to serve until the company's 2029 annual meeting, or until a successor is duly elected and qualified, or until earlier death, resignation, or removal.¹ Kush received 70,338,595 votes for and 12,770,121 withheld, while Berman received 64,127,395 votes for and 18,981,321 withheld, with 23,911,956 broker non-votes for each.¹

Shareholders also ratified CohnReznick LLP as the company's independent registered public accounting firm for fiscal year 2026, with 106,910,712 votes in favor, 96,428 against, and 13,532 abstentions.¹

On governance matters, stockholders approved increasing the shares available under the 2020 Equity Incentive Plan by 3,000,000 shares, with 60,795,802 votes for, 22,135,512 against, 177,402 abstentions, and 23,911,956 broker non-votes.¹ They also approved the certificate amendment limiting officer liability under Delaware law, with 82,321,246 votes for, 779,416 against, and 8,054 abstentions.¹

On compensation matters, the advisory say-on-pay vote passed with 61,237,304 votes for, 21,648,671 against, and 222,741 abstentions.¹ On the frequency of future say-on-pay votes, 77,456,671 votes favored an annual cadence, and the company has determined it will hold these advisory votes annually until the next stockholder vote on frequency.¹